BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23537721)

  • 1. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
    Martinowitz U; Lubetsky A
    Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
    Santagostino E; Martinowitz U; Lissitchkov T; Pan-Petesch B; Hanabusa H; Oldenburg J; Boggio L; Negrier C; Pabinger I; von Depka Prondzinski M; Altisent C; Castaman G; Yamamoto K; Álvarez-Roman MT; Voigt C; Blackman N; Jacobs I;
    Blood; 2016 Apr; 127(14):1761-9. PubMed ID: 26755710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
    Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
    Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
    J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.
    Herzog E; Harris S; Henson C; McEwen A; Schenk S; Nolte MW; Pragst I; Dickneite G; Schulte S; Zollner S
    Thromb Res; 2014 May; 133(5):900-7. PubMed ID: 24680550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.
    Mancuso ME; Lubetsky A; Pan-Petesch B; Lissitchkov T; Nagao A; Seifert W; Li Y; Santagostino E
    J Thromb Haemost; 2020 May; 18(5):1065-1074. PubMed ID: 32078256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.
    Santagostino E; Negrier C; Klamroth R; Tiede A; Pabinger-Fasching I; Voigt C; Jacobs I; Morfini M
    Blood; 2012 Sep; 120(12):2405-11. PubMed ID: 22859609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
    Oldenburg J; Yan S; Maro G; Krishnarajah G; Tiede A
    Curr Med Res Opin; 2020 Jan; 36(1):9-15. PubMed ID: 31469321
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
    Kenet G; Chambost H; Male C; Lambert T; Halimeh S; Chernova T; Mancuso ME; Curtin J; Voigt C; Li Y; Jacobs I; Santagostino E;
    Thromb Haemost; 2016 Sep; 116(4):659-68. PubMed ID: 27583313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
    Kenet G; Chambost H; Male C; Halimeh S; Lambert T; Li Y; Seifert W; Santagostino E
    Thromb Haemost; 2020 Apr; 120(4):599-606. PubMed ID: 32185782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
    Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
    J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new era for hemophilia B treatment.
    Taylor JA; Kruse-Jarres R
    Blood; 2016 Apr; 127(14):1734-6. PubMed ID: 27056991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.